TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi), a leading Japanese pharmaceutical company specializing in infectious diseases, vaccines, and hematology, announced today that it has established a new office in the Boston area, USA, and is initiating venture investments in the life science and healthcare fields.

东京--（商业新闻短讯）--明治精嘉制药有限公司（总部：东京，总裁兼代表董事：小林大吉一郎）是一家专注于传染病、疫苗和血液学的领先日本制药公司，今天宣布在美国波士顿地区设立新办事处，并开始在生命科学和医疗保健领域进行风险投资。

Through its investment activities, Meiji Seika Pharma aims to discover and develop cutting-edge therapies and contribute to solving unmet medical needs of patients worldwide, reflecting the company’s unwavering commitment to innovation and global health..

通过其投资活动，明治精嘉制药旨在发现和开发尖端疗法，并为解决全球患者未满足的医疗需求做出贡献，这反映了该公司对创新和全球健康的坚定承诺。。

Meiji Seika Pharma was founded in 1916, started pharmaceutical business in 1946, and has grown to be a leading Japanese pharmaceutical company. The company has been at the forefront of research and development of therapeutics and vaccines for infectious diseases. In December 2023, Meiji Seika Pharma obtained the world’s first marketing approval for a self-amplifying mRNA vaccine against COVID-19 (Kostaive®).

明治精嘉制药成立于1916年，1946年开始制药业务，现已发展成为日本领先的制药公司。该公司一直处于传染病治疗和疫苗研发的前沿。。

In addition to its focus on infectious diseases area, Meiji Seika Pharma is dedicated to drug discovery and development in hematology and oncology. The company has developed and launched a selective ROCK2 inhibitor (belumosudil mesilate) for the treatment of chronic GVHD, and an HDAC inhibitor (tucidinostat) for ATLL and PTCL in Japan.

除了专注于传染病领域外，明治精嘉制药还致力于血液学和肿瘤学的药物发现和开发。该公司在日本开发并推出了用于治疗慢性GVHD的选择性ROCK2抑制剂（甲磺酸贝鲁莫司地），以及用于ATLL和PTCL的HDAC抑制剂（tucidinostat）。

As a fully integrated pharmaceutical company, it has over 5,500 employees worldwide..

作为一家全面整合的制药公司，它在全球拥有5500多名员工。。

Meiji Seika Pharma will expand its presence in the Boston area by opening a new office and explore venture investments at the center of innovation. Located at CIC Cambridge (One Broadway, Cambridge, MA 02142), the new office will act as a strategic hub, fostering investment opportunities that align with the Meiji Seika Pharma’s current vision for growth and innovation.

明治精嘉制药将在波士顿地区开设新办事处，并在创新中心探索风险投资，从而扩大其业务。新办公室位于中投剑桥（One Broadway，Cambridge，MA 02142），将作为一个战略中心，创造与明治精嘉制药当前增长和创新愿景相一致的投资机会。

Meiji Seika Pharma will initiate investments in startups and venture capital firms that focus on drug discovery and innovative platform technology. The office is organized as part of Meiji Pharma USA Inc., a subsidiary of Meiji Seika Pharma..

明治精嘉制药将对专注于药物发现和创新平台技术的初创公司和风险投资公司进行投资。该办公室是明治制药美国公司的一部分，明治制药美国公司是明治制药的子公司。。

“We are pleased to deepen our expertise in infectious diseases area as well as other focus areas,” said Mr. Daikichiro Kobayashi, President and Representative Director of Meiji Seika Pharma. “Our Boston office will facilitate collaboration with pioneering bioventures and startups, furthering our mission to develop innovative solutions such as groundbreaking therapeutics and beyond the pills.”.

明治精嘉制药总裁兼代表董事DaikichiroKobayashi先生表示：“我们很高兴能够加深我们在传染病领域以及其他重点领域的专业知识。”。“我们的波士顿办事处将促进与开创性的生物风险投资公司和初创公司的合作，进一步推动我们开发创新解决方案的使命，如开创性的治疗方法和超越药丸。”。

Meiji Seika Pharma’s challenges into these innovative approaches show its commitment to addressing critical health challenges and improving patient outcomes on a global scale. By leveraging the Boston area’s dynamic ecosystem, the company aims to accelerate its research and development efforts and bring breakthrough therapies to global market..

明治Seika Pharma对这些创新方法的挑战表明，它致力于解决关键的健康挑战，并在全球范围内改善患者的预后。通过利用波士顿地区的动态生态系统，该公司旨在加速其研发工作，并将突破性疗法带入全球市场。。